Table 1 Characteristics of artemether–lumefantrine samples collected from high and low malaria transmission settings in Uganda, June–December 2021 (N = 74)
From: Pharmacopeial quality of artemether–lumefantrine anti-malarial agents in Uganda
S/no. | Brand name | No. of samples n (%) | Malaria transmission setting | No. of batches | Label claim (AL/mg) | Manufacturer, country of origin | |
|---|---|---|---|---|---|---|---|
20/120 | 40/240 | ||||||
1 | LONARTa | 25 (33.8%) | Low | 8 | 8 | 0 | BLISS GVS Pharma Ltd, India |
High | 17 | 13 | 1 | ||||
2 | ARTEFANb | 15 (20.3%) | Low | 5 | 5 | 0 | AJANTA Pharma Ltd, India |
High | 10 | 7 | 1 | ||||
3 | LUMARTEMc | 3 (4.1%) | Low | 1 | 1 | 0 | CIPLA Ltd, India |
High | 2 | 1 | 0 | ||||
4 | CO-METHER | 5 (6.8%) | Low | 2 | 2 | 0 | AGOG Pharma Ltd, India |
High | 3 | 3 | 0 | ||||
5 | KOMEFAN 140 | 1 (1.4%) | Low | 0 | 0 | 0 | MYLAN Laboratories Ltd, India |
High | 1 | 1 | 0 | ||||
6 | COMBIART | 5 (6.8%) | Low | 0 | 0 | 0 | STRIDES SHASUN Ltd, India |
High | 5 | 5 | 0 | ||||
7 | LONART-DSd | 1 (1.4%) | Low | 0 | 0 | 0 | BLISS GVS Pharma Ltd, India |
High | 1 | 0 | 0 | ||||
8 | LUMERAX | 1 (1.4%) | Low | 0 | 0 | 0 | IPCA laboratories Ltd, India |
High | 1 | 1 | 0 | ||||
9 | LARIACT | 3 (4.1%) | Low | 0 | 0 | 0 | SKANT Healthcare Ltd, India |
High | 3 | 3 | 0 | ||||
10 | Cach-ART | 2 (2.7%) | Low | 0 | 0 | 0 | CACHET Pharma PVT Ltd, India |
High | 2 | 2 | 0 | ||||
11 | LUMAREN | 2 (2.7%) | Low | 2 | 2 | 0 | RENE Industries Ltd, Uganda |
High | 0 | 0 | 0 | ||||
12 | COARTEM | 1 (1.4%) | Low | 1 | 1 | 0 | NOVARTIS PHARMA AG, Switzerland |
High | 0 | 0 | 0 | ||||
13 | KOMEFAN | 1 (1.4%) | Low | 0 | 0 | 0 | MYLAN Laboratories Ltd, India |
High | 1 | 1 | 0 | ||||
14 | Not indicated | 4 (5.4%) | Low | 4 | 4 | 0 | IPCA laboratories Ltd, India |
High | 1 | 1 | 0 | ||||
15 | LUMITER | 6 (8.1%) | Low | 3 | 3 | 0 | MACLEODS Pharma Ltd, India |
High | 3 | 3 | 0 | ||||